Skip to main content

Thomas Thomas T.'s Form 4 filing

Opiant Pharmaceuticals, Inc. (OPNT) · filed Sep 23, 2021

Accession no.
0001385508-21-000138
Filed
Sep 23, 2021
Trade date
Sep 21-22, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $38.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Thomas Thomas T.CIK 0001689819Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 21, 2021Common StockMOption exerciseAcquired+2,000$10.00+$20,00010,107Direct
Sep 21, 2021Common StockSSaleDisposed−60$24.07−$1,444.210,047Direct
Sep 21, 2021Common StockSSaleDisposed−771$24.12−$18,596.529,276Direct
Sep 22, 2021Common StockMOption exerciseAcquired+1,834$10.00+$18,34011,110Direct
Sep 22, 2021Common StockSSaleDisposed−735$25.02F5−$18,389.710,375Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 21, 2021Common StockMOption exerciseDisposed−2,000$0.00$01,834Direct
Sep 22, 2021Common StockMOption exerciseDisposed−1,834$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F5

This transaction was executed in multiple trades at prices ranging from $24.52 to $25.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)